-
Je něco špatně v tomto záznamu ?
Deazaflavin Inhibitors of TDP2 with Cellular Activity Can Affect Etoposide Influx and/or Efflux
E. Komulainen, L. Pennicott, D. Le Grand, KW. Caldecott,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
C6563/A16771
Cancer Research UK - United Kingdom
110578/Z/15/Z
Wellcome Trust - United Kingdom
- MeSH
- aza sloučeniny chemie MeSH
- biologický transport MeSH
- buněčné linie MeSH
- DNA vazebné proteiny antagonisté a inhibitory MeSH
- etoposid farmakokinetika MeSH
- flaviny chemie farmakokinetika farmakologie MeSH
- fosfodiesterasy MeSH
- inhibitory topoisomerasy II farmakokinetika MeSH
- knihovny malých molekul farmakologie MeSH
- kur domácí MeSH
- lidé MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Tyrosyl DNA phosphodiesterase 2 (TDP2) facilitates the repair of topoisomerase II (TOP2)-linked DNA double-strand breaks and, as a consequence, is required for cellular resistance to TOP2 "poisons". Recently, a deazaflavin series of compounds were identified as potent inhibitors of TDP2, in vitro. Here, however, we show that while some deazaflavins can induce cellular sensitivity to the TOP2 poison etoposide, they do so independently of TDP2 status. Consistent with this, both the cellular level of etoposide-induced TOP2 cleavage complexes and the intracellular concentration of etoposide was increased by incubation with deazaflavin, suggesting an impact of these compounds on etoposide uptake/efflux. In addition, deazaflavin failed to increase the level of TOP2 cleavage complexes or sensitivity induced by m-AMSA, which is a different class of TOP2 poison to which TDP2-defective cells are also sensitive. In conclusion, while deazaflavins are potent inhibitors of TDP2 in vitro, their limited cell permeability and likely interference with etoposide influx/efflux limits their utility in cells.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006361
- 003
- CZ-PrNML
- 005
- 20200526083859.0
- 007
- ta
- 008
- 200511s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acschembio.9b00144 $2 doi
- 035 __
- $a (PubMed)31091068
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Komulainen, Emilia $u Genome Damage and Stability Centre, School of Life Sciences , University of Sussex , Falmer, Brighton , BN1 9RQ , United Kingdom.
- 245 10
- $a Deazaflavin Inhibitors of TDP2 with Cellular Activity Can Affect Etoposide Influx and/or Efflux / $c E. Komulainen, L. Pennicott, D. Le Grand, KW. Caldecott,
- 520 9_
- $a Tyrosyl DNA phosphodiesterase 2 (TDP2) facilitates the repair of topoisomerase II (TOP2)-linked DNA double-strand breaks and, as a consequence, is required for cellular resistance to TOP2 "poisons". Recently, a deazaflavin series of compounds were identified as potent inhibitors of TDP2, in vitro. Here, however, we show that while some deazaflavins can induce cellular sensitivity to the TOP2 poison etoposide, they do so independently of TDP2 status. Consistent with this, both the cellular level of etoposide-induced TOP2 cleavage complexes and the intracellular concentration of etoposide was increased by incubation with deazaflavin, suggesting an impact of these compounds on etoposide uptake/efflux. In addition, deazaflavin failed to increase the level of TOP2 cleavage complexes or sensitivity induced by m-AMSA, which is a different class of TOP2 poison to which TDP2-defective cells are also sensitive. In conclusion, while deazaflavins are potent inhibitors of TDP2 in vitro, their limited cell permeability and likely interference with etoposide influx/efflux limits their utility in cells.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a aza sloučeniny $x chemie $7 D001372
- 650 _2
- $a biologický transport $7 D001692
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a kur domácí $7 D002645
- 650 _2
- $a DNA vazebné proteiny $x antagonisté a inhibitory $7 D004268
- 650 _2
- $a etoposid $x farmakokinetika $7 D005047
- 650 _2
- $a flaviny $x chemie $x farmakokinetika $x farmakologie $7 D005415
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a fosfodiesterasy $7 D010727
- 650 _2
- $a knihovny malých molekul $x farmakologie $7 D054852
- 650 _2
- $a inhibitory topoisomerasy II $x farmakokinetika $7 D059005
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pennicott, Lewis $u Sussex Drug Discovery Centre, School of Life Sciences , University of Sussex , Falmer, Brighton , BN1 9RQ , United Kingdom.
- 700 1_
- $a Le Grand, Darren $u Sussex Drug Discovery Centre, School of Life Sciences , University of Sussex , Falmer, Brighton , BN1 9RQ , United Kingdom.
- 700 1_
- $a Caldecott, Keith W $u Genome Damage and Stability Centre, School of Life Sciences , University of Sussex , Falmer, Brighton , BN1 9RQ , United Kingdom. Department of Genome Dynamics , Institute of Molecular Genetics of the Czech Academy of Sciences , 142 20 Prague , 4, Czech Republic.
- 773 0_
- $w MED00179502 $t ACS chemical biology $x 1554-8937 $g Roč. 14, č. 6 (2019), s. 1110-1114
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31091068 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200526083856 $b ABA008
- 999 __
- $a ok $b bmc $g 1525219 $s 1096417
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 14 $c 6 $d 1110-1114 $e 20190516 $i 1554-8937 $m ACS chemical biology $n ACS Chem Biol $x MED00179502
- GRA __
- $a C6563/A16771 $p Cancer Research UK $2 United Kingdom
- GRA __
- $a 110578/Z/15/Z $p Wellcome Trust $2 United Kingdom
- LZP __
- $a Pubmed-20200511